Fabeckstrasse 30
14195 Berlin

Phone: +49 30 84 17 88 0
Fax: +49 30 84 17 88 50
Stock symbol: MGN.FSE


Company Overview:
MOLOGEN AG is an expanding biotechnology company located in Berlin and specializes in the development of DNA-based therapeutics and vaccines against diseases with a high medical demand. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for the company’s business activities which are focused on cancer treatment and the fight against infectious diseases in humans and domestic animals.
Founded in 1998, MOLOGEN was one of the first German biotechnology companies to go public. MOLOGEN AG shares are listed on the General Standard segment of the Frankfurt Stock Exchange (ISIN DE 0006637200).

Novel TLR9 Agonist dSLIM® (double Stem Loop ImmunoModulator): dumbbell-shaped molecule with two single-stranded loops that are connected by a double-stranded stem, consisting of only non-coding DNA without any chemical modification; action of dSLIM® molecule is mediated through binding to TLR9 and results in a broad activation of the immune system and thus initiates a fast defensive reaction against infectious agents

MIDGE® (Minimalistic Immunogenically Defined Gene Expression): DNA-vector that exclusively contains the clinically relevant genetic information; MIDGE® features a linear DNA pattern and is covalently closed by single-stranded hairpin structures at both ends; allow for outstanding versatility due to their hairpin tails; most prominent paradigm is the MIDGE®-Th1 vector which induces a Th1-type cellular immune response and is therefore well suited for DNA vaccination against infectious diseases